Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Learn more about:
Related Clinical Trial
A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors A Study of a New Way to Treat Children With a Brain Tumor Called NGGCT Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Symptom Management for YA Cancer Survivors A Study of miRNA 371 in Patients With Germ Cell Tumors Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Aflac ST0901 CHOANOME – Sirolimus in Solid Tumors Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) A Pilot RCT of the PRISM Intervention for AYAs With Cancer Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Molecular-Guided Therapy for Childhood Cancer EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Busulfan in Treating Children and Adolescents With Refractory CNS Cancer CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy ABT-751 in Treating Young Patients With Refractory Solid Tumors Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Collecting and Storing Tissue From Young Patients With Cancer Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Everolimus in Refractory Testicular Germ Cell Cancer Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors First Line TIP in Poor Prognosis TGCTs. Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Disulfiram and Cisplatin in Refractory TGCTs. Role of Axumin PET Scan in Germ Cell Tumor Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors Study Evaluating the Impact of Short Message Service on Compliance With Surveillance of Patients With Germ-cell Tumors Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01 Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors Germ Cell Tumor and Testicular Tumor DNA Registry A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

Brief Title

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Official Title

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study

Brief Summary

      Children with brain tumors who have had radiation therapy are at risk for problems with
      attention, memory, and problem solving. Such problems may cause difficulty in school and
      daily life. Memantine, the drug being used for this study, is not yet approved for use in
      children by the U.S. Food and Drug Administration. However, studies have shown some
      improvements in memory for patients with dementia, Attention Deficit Hyperactivity Disorder,
      and autism. Scientists have also used this medication for adult cancer patients receiving
      radiation therapy with results showing less cognitive declines over time compared to patients
      taking a placebo (inactive pill). These studies have also shown few side effects.

      This is a pilot/feasibility study and the first known study involving children with a cancer
      diagnosis or brain tumor.

      PRIMARY OBJECTIVES:

        -  To estimate the participation rate in a study of memantine used as a neuro-protective
           agent in children undergoing radiotherapy for localized brain tumors (low grade glioma,
           craniopharyngioma, ependymoma, or germ cell tumor)

        -  To estimate the rate of memantine medication adherence

        -  To estimate the rate of completion of cognitive assessments

      SECONDARY OBJECTIVES:

        -  To estimate the effect size of change in neurobehavioral outcomes (cognitive, social,
           quality of life, neurologic) associated with memantine

        -  To evaluate the frequency and nature of memantine side effects as measured by the
           Systematic Assessment for Treatment Emergent Events (SAFTEE)
    

Detailed Description

      Participants will be randomized to take part in one of two groups:

        -  The Memantine Group will be prescribed memantine at a dosage following FDA-approved
           adult labeling. A low dose will initially be given beginning at least two weeks (± 7
           days) prior to beginning radiation therapy. The dose will increase until participants
           reach the target dose of 20 mg/day. Memantine will be given for a total of 12 weeks.

        -  The Placebo Group will be prescribed identical capsules with no active drug. The placebo
           drug will be given in the same dose and frequency as described for the Memantine group.

      Participants will undergo the same evaluations and monitoring throughout the medication
      phase. Assessments will be done at baseline prior to study start, with follow-up assessments
      at 6 weeks (end of radiation therapy), and 12 weeks (end of study medication). Psychological
      testing to measure attention, working memory, problem solving, intelligence and academics
      will be done for each participant. Caregivers will also complete questionnaires about
      attention, problem solving, mood and interpersonal interactions. Caregivers will also be
      asked to complete a questionnaire about the family's general characteristics and medical
      history.

      At the time points noted above, blood work, vital signs and echocardiograms will be obtained,
      and the study neurologist will examine the participant to monitor side effects and
      neurological functioning. A study nurse will contact the participant once per week during the
      12 weeks of medication administration to identify possible medication-related side effects
      and to check on rate of compliance with taking the medication. A remote app will be installed
      on the participant's home computer or cell phone to help remind them to take the medication
      and track success. At one year post medication, psychological and neurological examinations
      will be repeated.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Percent of approached participants who consent to study participation

Secondary Outcome

 Change in neurobehavioral outcome

Condition

Glioma of Brain

Intervention

Memantine

Study Arms / Comparison Groups

 Memantine
Description:  Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

50

Start Date

November 7, 2017

Completion Date

March 2023

Primary Completion Date

March 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Age 6 years to 21 years at time of study enrollment

          -  Diagnosis of localized low grade glioma [e.g., pilocytic astrocytoma, optic pathway
             glioma, ogligodendroglioma, ganglioglioma, pleomorphic xanthoastrocytoma (PXA)],
             craniopharyngioma, ependymoma, or germ cell tumor

          -  Initiating focal cranial radiation therapy (photon or proton)

          -  Laboratory tests [transaminases (ALT, AST, ALP), BUN and creatinine not greater than
             twice normal] and normal ECG

          -  Speak, read and understand English sufficiently to complete study assessments

          -  Adequate vision and hearing for valid completion of study measures

          -  Negative βHCG pregnancy test among females of childbearing age

          -  Participant must be able to swallow pills (psychology staff will be available to
             assist with pill swallowing training if needed)

          -  Parent/Legal guardian available and able to speak, read and understand English

        Exclusion Criteria:

          -  Medical disorder that would endanger subject's well-being (e.g., uncorrected
             hypothyroidism, cardiac arrhythmia, hypertension requiring treatment, sick sinus
             syndrome, prolonged QTc)

          -  History of significant neurological disease including poorly controlled seizures
             (i.e., > 1 seizure per month; anti-epileptic medications are acceptable), stroke, or
             head injury with loss of consciousness

          -  Psychiatric condition that would preclude or take precedence over study participation
             (e.g., active psychosis, suicidal ideation)

          -  IQ below 70 based on baseline/screening assessment

          -  Treatment with psychotropic medication (psychostimulant, antidepressant, anxiolytic,
             antipsychotic) within the past two weeks, unless being prescribed specifically as an
             anti-emetic

          -  History of substance abuse

          -  History of hypersensitivity or reaction to NMDA receptor antagonists

          -  History of prior cranial radiation therapy
      

Gender

All

Ages

6 Years - 21 Years

Accepts Healthy Volunteers

No

Contacts

Heather M. Conklin, PhD, 866-278-5833, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03194906

Organization ID

MEMCRT

Secondary IDs

R21CA218625

Responsible Party

Sponsor

Study Sponsor

St. Jude Children's Research Hospital

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Heather M. Conklin, PhD, Principal Investigator, St. Jude Children's Research Hospital


Verification Date

April 2021